This form must be completed for all recipients of cellular therapy (non-HCT), including post-HCT “DCI / DLI” infusions. For recipients of hematopoietic cellular transplants, complete the appropriate HCT follow-up form.

The Post-Cellular Therapy Essential Data (Post-CTED) follow-up form focuses on key follow-up information for each reporting period, including the survival status of the recipient, causes of death if the recipient died in the period since the last report, additional cellular infusions performed, response to the cellular therapy, relapse, current hematologic findings, development of new malignancies, persistence of the cellular product (product specific), development and severity of toxicities (e.g. cytokine release syndrome, neurotoxicity), infection and fertility information.

The Post-CTED Form must be completed at the following time points post-cellular therapy: 100 days, six months, and annually thereafter. The follow-up reporting schedule is determined by whether the product is genetically modified or not. The structure of the Post-CTED is such that each form should fit on a timeline with distinct start and stop dates that do not overlap any other forms.

Combined follow up
In scenarios where both HCT and cellular therapy forms are being completed, there are two scenarios where the Cellular Therapy Essential Data Follow-Up (4100) form is completed:

Example 1. Cellular therapy after HCT: completion of this form should be based on the time period in relation to the CT infusion date (i.e. 100 days after the CT infusion date). The visit ID and date of contact should match between the corresponding Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

Example 2. HCT after cellular therapy: completion of this form should be based on the time period in relation to the HCT infusion date (i.e. 100 days after the HCT infusion date). The visit ID and date of contact should match between the corresponding Post-HSCT Data (2100) or Post-Transplant Essential Data (2450).

Duplicate questions between HCT and cellular therapy forms may be disabled on the Post-CTED. A full list of enabled/disabled fields can be found on the “Subsequent Infusions – Updates to Follow-Up Reporting section of the Data Management Guide. Illustrations of the combined follow up scenarios can also be found the Guide.

Links to sections of form:
Q1: Product
Q2-3: Survival
Q4-8: Subsequent Cellular Infusions
Q9-11: Best Response to Cellular Therapy
Q12-20: Peripheral Blood Count Recovery
Q21-22: Disease Relapse or Progression
Q23-33: Current Hematologic Findings
Q34: New Malignancy, Lymphoproliferative or Myeloproliferative Disease/Disorder
Q35-59: Persistence of Cells
Q60-79: Graft vs. Host Disease
Q80-170: Toxicities
Q171-175: Infection
Q176-177: Pregnancy Status

Manual updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date Manual Section Add/Remove/Modify Description
4/11/22 4100 Post-CTED Add Clarification added on reporting COVID-19 infections for subsequent infusions & possible reporting scenarios: Do NOT report an infection in the following scenarios:
A recipient only has a positive antibody result.
The recipient was symptomatic and treated but COVID-19 diagnostic testing was not performed and / or COVID-19 diagnostic testing was performed and negative.
DO report an infection in the following scenarios:
A recipient has a positive COVID-19 diagnostic result (PCR or antigen) or if treatment was given or if the recipient was asymptomatic.
A recipient has a positive antibody result and a positive COVID-19 diagnostic test (PCR or antigen)
4/11/2022 4100 Post-CTED Add COVID-19 Reinfection blue box added above Q204-208: Reporting COVID-19 Reinfection: There have been cases of recipients recovering from COVID-19 infection, only to later test positive again. For CIBMTR purposes, a new COVID-19 infection should be reported when a recipient tests positive again >21 days from resolution (resolution defined as no signs or symptoms of infection, or a negative diagnostic test). Added for clarification
4/11/2022 4100: Q204-213: Infection Add COVID-19 Reinfection blue box added above Q204-208: Reporting COVID-19 Reinfection: There have been cases of recipients recovering from COVID-19 infection, only to later test positive again. For CIBMTR purposes, a new COVID-19 infection should be reported when a recipient tests positive again >21 days from resolution (resolution defined as no signs or symptoms of infection, or a negative diagnostic test).
4/11/2022 4100: Q204-213: Infection Add Clarification added in regard to revaccination post-infusion: Indicate if the recipient received a vaccine for COVID-19 (one dose without a planned second dose, first dose with planned second dose, second dose, third dose, and / or booster dose) within the current reporting period. If the recipient did not receive a vaccine for COVID-19 or it is not known if the recipient received a vaccine, select No or Unknown, respectively, and continue with question 214. Revaccination Post-Infusion: When vaccines are given post-infusion, the physician should make the determination on whether the doses are part of the primary series of vaccines, third primary dose, boosters, or revaccination. If a recipient receives a new course of COVID vaccines following infusion as revaccination, report the vaccines as a new series. The most up to date CDC COVID-19 vaccine information for immunocompromised people can be found here.
4/11/2022 4100: Q204-213: Infection Modify Updated blue box above Q210-211 how to report multiple vaccine doses: COVID-19 Vaccine Doses
FormsNet3SM application: Complete questions 210 – 213 to report all COVID-19 vaccine doses received in the current reporting period by adding an additional instance in the FormsNet3SM application. A separate instance should be added for each dose.
4/11/2022 4100: Q204-213: Infection Modify/Add Updated question instructions: For the reported dose, specify the vaccine brand the recipient received. If the vaccine brand is not listed, select Other type and specify. If the vaccine brand is unknown, leave the field blank and override the error as Unknown. Third dose versus Booster dose blue box added above question 210-211: Third dose versus Booster dose: To determine between a third dose and a booster dose, seek clinician clarification, as needed, using the guidelines listed below:
Third dose: An additional primary dose required for recipients who did not build enough protection from their primary vaccine series, typically for immunocompromised individuals
Booster dose: Administered to recipients who have enough protection after completing their primary vaccine series but then protection decreases over time
Primary vaccine series: Two doses of Pfizer-BioNTech or Moderna One dose of Johnson & Johnson’s Janssen.
4/11/2022 4100: Q204-213: Infection Modify Updated question instructions: For the reported dose, specify the vaccine dose the recipient in the current reporting period and specify the date when the dose was received
4/11/2022 4100: Q89-202: Toxicities Add Additional example (#5) added to clarify hypogammaglobulinemia reporting: Example 5. For an adult recipient, IgG levels were below 600 mg/dL pre-infusion and immunoglobulin replacement therapy (IVIG) was given pre-infusion. Post-infusion, all IgG values were greater than 600 mg/dL and never dropped below 600 mg/mL. This is not reported as a toxicity since the IgG levels were never below 600 mg/dL after infusion.
1/28/2022 4100: Cellular Therapy Essential Data Follow-Up Modify Version 8 of the 4100: Cellular Therapy Essential Data Follow-Up section of the Forms Instruction Manual released. Version 8 corresponds to revision 8 of the Form 4100.
Last modified: Apr 11, 2022

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.